In patients who initially received chemo-hormonal first-line therapy for metastatic prostate cancer followed by abiraterone/enzalutamide for castration-resistant disease, would you re-challenge with docetaxel?

As we all know, very few things regarding therapeutic sequencing in prostate cancer are straightforward. Retreatment with docetaxel was used relatively commonly in the past in patients with mcrpc, especially in those with good initial responses primarily for want of other agents. In this setting, re...

The median duration of response for docetaxel in the mCRPC setting is relatively short (e.g. median PFS 5.3 months in FIRSTANA; Oudard et al., PMID 28753384) but can be longer than that expected from the treatment duration of docetaxel in the mHSPC setting (e.g. median PFS 9.1 months in docetaxel/pl...